Publications by authors named "V Brixner"

Introduction: In Germany, demand for platelet transfusion is maintained or even increasing, despite a decrease in whole blood donations observed in the last decade. The shelf-life of platelet concentrates (PCs) in Germany is 4 days, which can be extended to 5 days if appropriate safety measures are used. This short shelf-life leads to decreased PC availability.

View Article and Find Full Text PDF

Pathogen reduction (PR) technologies for blood components have been established to reduce the residual risk of known and emerging infectious agents. THERAFLEX UVPlatelets, a novel UVC light-based PR technology for platelet concentrates, works without photoactive substances. This randomized, controlled, double-blind, multicenter, noninferiority trial was designed to compare the efficacy and safety of UVC-treated platelets to that of untreated platelets in thrombocytopenic patients with hematologic-oncologic diseases.

View Article and Find Full Text PDF

Background: The INTERCEPT™ Blood System for Red Blood Cells (RBCs) utilizes amustaline (S-303) and glutathione (GSH) to inactivate pathogens and leukocytes in transfused RBCs. Treatment-emergent low titer non-hemolytic antibodies to amustaline/GSH RBC were detected in clinical trials using a prior version of the process. The amustaline/GSH process was re-formulated to decrease S-303 RBC adduct formation.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness of amustaline-treated red blood cells (RBCs) compared to conventional RBCs to enhance the safety of transfusions and prevent disease transmission during cardiac surgery.
  • Results showed that while amustaline-treated RBCs had a slightly lower mean hemoglobin content, they still met safety guidelines and did not lead to significant differences in clinical outcomes or adverse events.
  • The findings suggest that amustaline-treated RBCs are a viable option for transfusions, with no immune response detected and potential benefits for future studies on cardiac surgery.
View Article and Find Full Text PDF

Background: Several ultraviolet (UV) light-based pathogen inactivation (PI) technologies for platelet (PLT) products have been developed or are under development. Upon implementation of PI technologies, quality control measures are required to ensure consistent efficiency of the treatment process. Previous reports showed that amotosalen/UVA and riboflavin/UV-based PI technologies induce modifications of the PLT-derived mitochondrial DNA (mtDNA) that can be detected by polymerase chain reaction (PCR) inhibition assays.

View Article and Find Full Text PDF